Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.
2.

Expression of concern reaffirmed.

Curfman GD, Morrissey S, Drazen JM.

N Engl J Med. 2006 Mar 16;354(11):1193. Epub 2006 Feb 22. No abstract available.

3.

Response to expression of concern regarding VIGOR study.

Reicin A, Shapiro D.

N Engl J Med. 2006 Mar 16;354(11):1196-9. No abstract available.

PMID:
16544387
4.

Response to expression of concern regarding VIGOR study.

Bombardier C, Laine L, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A.

N Engl J Med. 2006 Mar 16;354(11):1196-9. Epub 2006 Feb 22. No abstract available.

5.
6.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group..

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

7.

The lessons of Vioxx--drug safety and sales.

Waxman HA.

N Engl J Med. 2005 Jun 23;352(25):2576-8. No abstract available.

8.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
9.

Is rofecoxib safer than naproxen?

Adelman A.

J Fam Pract. 2001 Mar;50(3):204. No abstract available.

PMID:
11252204
10.

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

J√ľni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.

Lancet. 2004 Dec 4-10;364(9450):2021-9.

PMID:
15582059
11.

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Graham DY, Jewell NP, Chan FK.

Am J Med Sci. 2011 Nov;342(5):356-64. doi: 10.1097/MAJ.0b013e3182113658.

12.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group..

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

13.

Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.

[No authors listed]

Ann Intern Med. 2003 Oct 7;139(7):I29. No abstract available.

PMID:
14530248
14.

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.

Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A.

Gastroenterology. 2002 Oct;123(4):1006-12.

PMID:
12360461
15.

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.

Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P Jr, Reicin AS, Giannini EH.

J Rheumatol. 2006 May;33(5):985-95. Epub 2006 Apr 1.

PMID:
16583464
16.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group..

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
17.
18.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
19.

Lapses at the new England journal of medicine.

Smith R.

J R Soc Med. 2006 Aug;99(8):380-2. No abstract available.

20.

The Vioxx fallout.

Palmer K.

Minn Med. 2005 Mar;88(3):26-30. No abstract available.

PMID:
15852592

Supplemental Content

Support Center